Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials

CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents

(2018) Shivani B. Kaushik et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

CME Part II Psoriasis: Which Therapy for Which Patient Focus on special populations and chronic infections

(2018) Shivani B. Kaushik et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: An integrated analysis from 11 clinical trials

(2018) R G Langley et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials

(2018) Philip Mease et al.   ARTHRITIS CARE & RESEARCH

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

(2018) Désirée van der Heijde et al.   LANCET

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor

(2018) Atul Deodhar et al.   Arthritis & Rheumatology

Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis

(2017) Eric Toussirot   EXPERT OPINION ON BIOLOGICAL THERAPY

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data

(2017) Bruce Strober et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

(2017) Peter Nash et al.   LANCET

Axial spondyloarthritis

(2017) Joachim Sieper et al.   LANCET

Psoriatic Arthritis

(2017) Christopher T. Ritchlin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

(2016) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study

(2016) A. Egeberg et al.   BRITISH JOURNAL OF DERMATOLOGY

A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution

(2016) Talia M. Muram et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis

(2016) Zenas Z.N. Yiu et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance

(2015) K L Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study

(2015) Agnete Malm Gulati et al.   ANNALS OF THE RHEUMATIC DISEASES

Cardiovascular risk management in patients with active Ankylosing Spondylitis: a detailed evaluation

(2015) Sjoerd C Heslinga et al.   BMC MUSCULOSKELETAL DISORDERS

Psoriasis

(2015) Wolf-Henning Boehncke et al.   LANCET

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study

(2014) Carmen Stolwijk et al.   ANNALS OF THE RHEUMATIC DISEASES

Psoriasis and smoking: a systematic review and meta-analysis

(2013) A.W. Armstrong et al.   BRITISH JOURNAL OF DERMATOLOGY

Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study

(2013) M. Dubreuil et al.   RHEUMATOLOGY

Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women

(2012) Wen-Qing Li et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-IL-17 mAbs herald new options in psoriasis

(2012) Ken Garber   NATURE BIOTECHNOLOGY

Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany

(2010) M Augustin et al.   ACTA DERMATO-VENEREOLOGICA

The burden of autoimmune disease: A comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis

(2009) Maryanne Makredes et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Psoriasis associated with ulcerative colitis and Crohn's disease

(2009) AD Cohen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY